Related Experiment Video
Updated: Oct 11, 2025

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Prognostic value of interleukin-6 in atrial fibrillation: A cohort study and meta-analysis
Xiaoyue Jia1, Xi Cheng2, Na Wu1
1Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University); Chongqing-People's Republic of China;Evidence-based Medicine and Clinical Epidemiology Center, Army Medical University (Third Military Medical University); Chongqing-People's Republic of China.
Insights
Elevated interleukin-6 (IL-6) levels predict stroke and mortality in atrial fibrillation (AF) patients. Adding IL-6 to the CHA2DS2-VASc score may improve AF management strategies.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- Interleukin-6 (IL-6) is a pro-inflammatory cytokine.
- Its prognostic value in atrial fibrillation (AF) requires further clarification.
- AF is a common arrhythmia associated with increased risk of stroke and mortality.
Purpose of the Study:
- To assess the predictive value of IL-6 for stroke and mortality in AF patients.
- To evaluate the incremental prognostic value of IL-6 when added to the CHA2DS2-VASc score.
- To validate these associations through a meta-analysis.
Main Methods:
- A cohort study of 217 newly diagnosed non-valvular AF patients followed for 27 months.
- Multivariate Cox regression analysis to assess IL-6 association with stroke and mortality.
- Meta-analysis of existing cohort studies and the current study.
Main Results:
- Elevated IL-6 was an independent predictor of stroke (HR=3.81) and mortality (HR=3.11) in the cohort.
- Adding IL-6 to CHA2DS2-VASc score showed improved stroke prediction (AUC 0.81 to 0.88).
- Meta-analysis confirmed IL-6 association with increased stroke (pooled HR=1.97) and mortality (pooled HR=2.73) risk.
Conclusions:
- Increased IL-6 levels are significantly linked to higher stroke and mortality risks in AF patients.
- IL-6 may serve as a valuable biomarker to refine AF risk stratification.
- Incorporating IL-6 into risk scores could aid in managing AF treatment.
Objective:
The prognostic value of interleukin-6 (IL-6) in patients with atrial fibrillation (AF) has not been fully elucidated. Therefore, we conducted a cohort study and a meta-analysis to assess the predictive value of IL-6 for stroke and mortality in patients with AF.
Methods:
A cohort study was performed in newly diagnosed non-valvular patients with AF. A total of 217 patients with AF were followed up for a mean of 27 months. A multivariate Cox regression analysis was used to evaluate the association between IL-6 and stroke/all-cause mortality. The incremental value was also assessed by adding IL-6 to the CHA2DS2-VASc score. Besides, a meta-analysis of all reported cohort studies and our cohort study was conducted to validate the association of circulating IL-6 and stroke/mortality in patients with AF.
Results:
Our cohort study showed that elevated plasma level of IL-6 was an independent risk factor for predicting stroke [hazard ratio (HR)=3.81; 95% confidence interval (CI), 1.11-13.05; p=0.033] and all-cause mortality (HR=3.11; 95% CI, 1.25-7.72; p=0.015) in patients with AF. Adding IL-6 levels to CHA2DS2-VASc score showed limited improvement of the predictive power for stroke [area under curve (AUC) from 0.81 to 0.88, p=0.006]. Meta-analysis confirmed that increased circulating level of IL-6 was significantly associated with increased risk of stroke (pooled HR=1.97; 95% CI, 1.22-3.17; p=0.006) and all-cause mortality (pooled HR=2.73; 95% CI, 2.29-3.25; p<0.001).
Conclusion:
Increased circulating level of IL-6 was significantly associated with greater risk of stroke and all-cause mortality in patients with AF. Adding IL-6 biomarker to the CHA2DS2-VASc score may help to determine the management of AF treatment.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The JAK-STAT Signaling Pathway
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

